The Long-Term Effect of Occlusal Therapy on Self-Administered Treatment Outcomes of TMD

Hirofumi Yatani, Hajime Minakuchi, Yoshizo Matsuka, Takuo Fujisawa, Atsushi Yamashita

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Because of a lack of substantial scientific data, the efficacy of occlusal therapy for the management of temporomandibular disorders (TMD) is still controversial. Of a total of 1405 consecutive TMD patients examined over the last 10 years, 369 (26.3%) were determined to have completed treatment at least 1 year before the present survey. A sample questionnaire was mailed to each patient in this sample population. The questionnaire failed to reach 46 patients; of the 323 patients who received the questionnaire, 260 (80.5%) responded. The mean duration of time between their last visit and this survey was 3.7 years. The questionnaire elicited information on treatment outcomes, present treatment needs, and current signs and symptoms. Participants were divided into two treatment groups: (a) those who underwent some occlusal therapies (Phase II) following successful reversible therapies (Phase I) (20 men and 114 women); and (b) those who underwent reversible therapy only (33 men and 93 women). Participants were further differentially diagnosed into five diagnostic subgroups of TMD, based on the clinical examination at the initial visit, tomography, and, for some patients, magnetic resonance imaging. The subgroups included myalgia, arthralgia, anterior disc displacement with and without reduction, and osteoarthritis/osteoarthrosis. Only 12.3% of the total population surveyed reported lack of improvement to an acceptable level and further need for treatment. The remaining patients reported satisfactory results in the reduction of TMD symptomatology and no further need for treatment, because their symptoms had either disappeared or improved to an acceptable level. Regardless of treatment groups and diagnostic subgroups, the current subjective signs and symptoms were negligible in most patients, and mean mouth openings were in the normal range. No particular diagnostic subgroups seemed to have significantly better outcome following Phase II occlusal therapy. These results suggest that the majority of TMD signs and symptoms improve to an acceptable level with only reversible therapy, and the long-term value of additional occlusal therapy following reversible therapy is minimal. Therefore, permanent occlusion-changing therapies apparently are not generally needed to maintain TMD symptom reduction over time.

Original languageEnglish
Pages (from-to)75-88
Number of pages14
JournalJournal of Orofacial Pain
Volume12
Issue number1
Publication statusPublished - 1998

Fingerprint

Temporomandibular Joint Disorders
Therapeutics
Signs and Symptoms
Osteoarthritis
Myalgia
Arthralgia

Keywords

  • Occlusal therapy
  • Questionnaire
  • Temporomandibular disorders
  • Treatment outcome

ASJC Scopus subject areas

  • Clinical Neurology
  • Dentistry(all)

Cite this

The Long-Term Effect of Occlusal Therapy on Self-Administered Treatment Outcomes of TMD. / Yatani, Hirofumi; Minakuchi, Hajime; Matsuka, Yoshizo; Fujisawa, Takuo; Yamashita, Atsushi.

In: Journal of Orofacial Pain, Vol. 12, No. 1, 1998, p. 75-88.

Research output: Contribution to journalArticle

Yatani, H, Minakuchi, H, Matsuka, Y, Fujisawa, T & Yamashita, A 1998, 'The Long-Term Effect of Occlusal Therapy on Self-Administered Treatment Outcomes of TMD', Journal of Orofacial Pain, vol. 12, no. 1, pp. 75-88.
Yatani, Hirofumi ; Minakuchi, Hajime ; Matsuka, Yoshizo ; Fujisawa, Takuo ; Yamashita, Atsushi. / The Long-Term Effect of Occlusal Therapy on Self-Administered Treatment Outcomes of TMD. In: Journal of Orofacial Pain. 1998 ; Vol. 12, No. 1. pp. 75-88.
@article{0d12305477bc4ad78fafdd88eef90080,
title = "The Long-Term Effect of Occlusal Therapy on Self-Administered Treatment Outcomes of TMD",
abstract = "Because of a lack of substantial scientific data, the efficacy of occlusal therapy for the management of temporomandibular disorders (TMD) is still controversial. Of a total of 1405 consecutive TMD patients examined over the last 10 years, 369 (26.3{\%}) were determined to have completed treatment at least 1 year before the present survey. A sample questionnaire was mailed to each patient in this sample population. The questionnaire failed to reach 46 patients; of the 323 patients who received the questionnaire, 260 (80.5{\%}) responded. The mean duration of time between their last visit and this survey was 3.7 years. The questionnaire elicited information on treatment outcomes, present treatment needs, and current signs and symptoms. Participants were divided into two treatment groups: (a) those who underwent some occlusal therapies (Phase II) following successful reversible therapies (Phase I) (20 men and 114 women); and (b) those who underwent reversible therapy only (33 men and 93 women). Participants were further differentially diagnosed into five diagnostic subgroups of TMD, based on the clinical examination at the initial visit, tomography, and, for some patients, magnetic resonance imaging. The subgroups included myalgia, arthralgia, anterior disc displacement with and without reduction, and osteoarthritis/osteoarthrosis. Only 12.3{\%} of the total population surveyed reported lack of improvement to an acceptable level and further need for treatment. The remaining patients reported satisfactory results in the reduction of TMD symptomatology and no further need for treatment, because their symptoms had either disappeared or improved to an acceptable level. Regardless of treatment groups and diagnostic subgroups, the current subjective signs and symptoms were negligible in most patients, and mean mouth openings were in the normal range. No particular diagnostic subgroups seemed to have significantly better outcome following Phase II occlusal therapy. These results suggest that the majority of TMD signs and symptoms improve to an acceptable level with only reversible therapy, and the long-term value of additional occlusal therapy following reversible therapy is minimal. Therefore, permanent occlusion-changing therapies apparently are not generally needed to maintain TMD symptom reduction over time.",
keywords = "Occlusal therapy, Questionnaire, Temporomandibular disorders, Treatment outcome",
author = "Hirofumi Yatani and Hajime Minakuchi and Yoshizo Matsuka and Takuo Fujisawa and Atsushi Yamashita",
year = "1998",
language = "English",
volume = "12",
pages = "75--88",
journal = "Journal of Orofacial Pain",
issn = "1064-6655",
publisher = "Quintessence Publishing Company",
number = "1",

}

TY - JOUR

T1 - The Long-Term Effect of Occlusal Therapy on Self-Administered Treatment Outcomes of TMD

AU - Yatani, Hirofumi

AU - Minakuchi, Hajime

AU - Matsuka, Yoshizo

AU - Fujisawa, Takuo

AU - Yamashita, Atsushi

PY - 1998

Y1 - 1998

N2 - Because of a lack of substantial scientific data, the efficacy of occlusal therapy for the management of temporomandibular disorders (TMD) is still controversial. Of a total of 1405 consecutive TMD patients examined over the last 10 years, 369 (26.3%) were determined to have completed treatment at least 1 year before the present survey. A sample questionnaire was mailed to each patient in this sample population. The questionnaire failed to reach 46 patients; of the 323 patients who received the questionnaire, 260 (80.5%) responded. The mean duration of time between their last visit and this survey was 3.7 years. The questionnaire elicited information on treatment outcomes, present treatment needs, and current signs and symptoms. Participants were divided into two treatment groups: (a) those who underwent some occlusal therapies (Phase II) following successful reversible therapies (Phase I) (20 men and 114 women); and (b) those who underwent reversible therapy only (33 men and 93 women). Participants were further differentially diagnosed into five diagnostic subgroups of TMD, based on the clinical examination at the initial visit, tomography, and, for some patients, magnetic resonance imaging. The subgroups included myalgia, arthralgia, anterior disc displacement with and without reduction, and osteoarthritis/osteoarthrosis. Only 12.3% of the total population surveyed reported lack of improvement to an acceptable level and further need for treatment. The remaining patients reported satisfactory results in the reduction of TMD symptomatology and no further need for treatment, because their symptoms had either disappeared or improved to an acceptable level. Regardless of treatment groups and diagnostic subgroups, the current subjective signs and symptoms were negligible in most patients, and mean mouth openings were in the normal range. No particular diagnostic subgroups seemed to have significantly better outcome following Phase II occlusal therapy. These results suggest that the majority of TMD signs and symptoms improve to an acceptable level with only reversible therapy, and the long-term value of additional occlusal therapy following reversible therapy is minimal. Therefore, permanent occlusion-changing therapies apparently are not generally needed to maintain TMD symptom reduction over time.

AB - Because of a lack of substantial scientific data, the efficacy of occlusal therapy for the management of temporomandibular disorders (TMD) is still controversial. Of a total of 1405 consecutive TMD patients examined over the last 10 years, 369 (26.3%) were determined to have completed treatment at least 1 year before the present survey. A sample questionnaire was mailed to each patient in this sample population. The questionnaire failed to reach 46 patients; of the 323 patients who received the questionnaire, 260 (80.5%) responded. The mean duration of time between their last visit and this survey was 3.7 years. The questionnaire elicited information on treatment outcomes, present treatment needs, and current signs and symptoms. Participants were divided into two treatment groups: (a) those who underwent some occlusal therapies (Phase II) following successful reversible therapies (Phase I) (20 men and 114 women); and (b) those who underwent reversible therapy only (33 men and 93 women). Participants were further differentially diagnosed into five diagnostic subgroups of TMD, based on the clinical examination at the initial visit, tomography, and, for some patients, magnetic resonance imaging. The subgroups included myalgia, arthralgia, anterior disc displacement with and without reduction, and osteoarthritis/osteoarthrosis. Only 12.3% of the total population surveyed reported lack of improvement to an acceptable level and further need for treatment. The remaining patients reported satisfactory results in the reduction of TMD symptomatology and no further need for treatment, because their symptoms had either disappeared or improved to an acceptable level. Regardless of treatment groups and diagnostic subgroups, the current subjective signs and symptoms were negligible in most patients, and mean mouth openings were in the normal range. No particular diagnostic subgroups seemed to have significantly better outcome following Phase II occlusal therapy. These results suggest that the majority of TMD signs and symptoms improve to an acceptable level with only reversible therapy, and the long-term value of additional occlusal therapy following reversible therapy is minimal. Therefore, permanent occlusion-changing therapies apparently are not generally needed to maintain TMD symptom reduction over time.

KW - Occlusal therapy

KW - Questionnaire

KW - Temporomandibular disorders

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=0032325401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032325401&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 75

EP - 88

JO - Journal of Orofacial Pain

JF - Journal of Orofacial Pain

SN - 1064-6655

IS - 1

ER -